4 results
Selected Clinical Trials of SGLT2 inhibitors in CVD and CKD
EMPA-REG OUTCOME - Empagliflozin lowered CV events
OUTCOME - Empagliflozin ... DECLARE-TIMI 58 - Dapagliflozin ... DAPA-CKD - Dapagliflozin ... EMPEROR-REDUCED - Empagliflozin ... SGLT2 #inhibitors #EBM
SGLT2 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits SGLT2 (sodium/glucose cotransporter 2) in the proximal tubule,
gliflozin): • Empagliflozin ... the three • Dapagliflozin ... loss (~2-3kg) • Empagliflozin ... ↓ CV mortality ... • Euglycemic diabetic
SGLT2 inhibitors, also called gliflozins, are a class of medications that alter essential physiology of the
treatment of type II diabetes ... (Invokana®), dapagliflozin ... (Farxiga®) and empagliflozin ... , #dapagliflozin ... , #empagliflozin
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

CONCLUSIONS:
Among patients with heart failure and a
Dapagliflozin in ... those who received dapagliflozin ... or absence of diabetes ... Kosalan Akilan #Dapagliflozin ... visualabstract #ebm